N4 Pharma PLC Total Voting Rights (6777H)

TIDMN4P

RNS Number : 6777H

N4 Pharma PLC

30 November 2022

30 November 2022

N4 Pharma plc

("N4 Pharma" or the "Company")

Total Voting Rights

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 233,780,349 ordinary shares of 0.4 pence each ("Ordinary Shares").

The total issued share capital of the Company consists of 233,780,349 Ordinary Shares. The Company does not hold any Ordinary Shares in Treasury. Therefore, the total current voting rights in the Company is 233,780,349 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 N4 Pharma plc 
 Nigel Theobald, CEO                        Via IFC Advisory 
 Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP             Tel: [phone] 
                                             0470 
 Nominated Adviser and Joint Broker 
 Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
 Vadim Alexandre/Abigail Wayne/Rob Rees 
  (Corporate Broking) 
 
 Turner Pope Investments (TPI) Limited      Tel: [phone] 
                                             0050 
 Joint Broker 
 Andy Thacker 
  James Pope 
 
 IFC Advisory Ltd                           Tel: [phone] 
                                             6630 
 Financial PR 
 Graham Herring 
 Zach Cohen 
 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBKPBQQBDDCDB

(END) Dow Jones Newswires

November 30, 2022 02:00 ET (07:00 GMT)